TKPHF Statistics

Total Valuation

Takeda Pharmaceutical Company has a market cap or net worth of 41.44 billion. The enterprise value is 71.64 billion.

Market Cap	41.44B
Enterprise Value	71.64B

Important Dates

The next estimated earnings date is Thursday, January 30, 2025.

Earnings Date	Jan 30, 2025
Ex-Dividend Date	Sep 27, 2024

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	+1.07%
Shares Change (QoQ)	+1.29%
Owned by Insiders (%)	n/a
Owned by Institutions (%)	n/a
Float	1.57B

Valuation Ratios

The trailing PE ratio is 20.47.

PE Ratio	20.47
Forward PE	n/a
PS Ratio	n/a
PB Ratio	n/a
P/TBV Ratio	n/a
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 8.15, with an EV/FCF ratio of 15.14.

EV / Earnings	35.39
EV / Sales	2.48
EV / EBITDA	8.15
EV / EBIT	17.15
EV / FCF	15.14

Financial Position

The company has a current ratio of 1.28, with a Debt / Equity ratio of 0.81.

Current Ratio	1.28
Quick Ratio	0.66
Debt / Equity	0.81
Debt / EBITDA	4.07
Debt / FCF	8.28
Interest Coverage	5.49

Financial Efficiency

Return on equity (ROE) is 4.15% and return on invested capital (ROIC) is 3.29%.

Return on Equity (ROE)	4.15%
Return on Assets (ROA)	2.77%
Return on Capital (ROIC)	3.29%
Revenue Per Employee	643,904
Profits Per Employee	41,075
Employee Count	49,281
Asset Turnover	0.31
Inventory Turnover	1.31

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -10.83% in the last 52 weeks. The beta is 0.50, so Takeda Pharmaceutical Company's price volatility has been lower than the market average.

Beta (5Y)	0.50
52-Week Price Change	-10.83%
50-Day Moving Average	26.69
200-Day Moving Average	27.02
Relative Strength Index (RSI)	39.26
Average Volume (20 Days)	5,873

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	n/a

Income Statement

In the last 12 months, Takeda Pharmaceutical Company had revenue of 31.73 billion and earned 2.02 billion in profits. Earnings per share was 1.27.

Revenue	31.73B
Gross Profit	20.93B
Operating Income	4.56B
Pretax Income	1.88B
Net Income	2.02B
EBITDA	9.27B
EBIT	4.56B
Earnings Per Share (EPS)	1.27

Full Income Statement

Balance Sheet

The company has 6.00 billion in cash and 39.15 billion in debt, giving a net cash position of -33.16 billion.

Cash & Cash Equivalents	6.00B
Total Debt	39.15B
Net Cash	-33.16B
Net Cash Per Share	n/a
Equity (Book Value)	48.31B
Book Value Per Share	30.47
Working Capital	4.65B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 6.12 billion and capital expenditures -1.39 billion, giving a free cash flow of 4.73 billion.

Operating Cash Flow	6.12B
Capital Expenditures	-1.39B
Free Cash Flow	4.73B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 65.95%, with operating and profit margins of 14.38% and 6.38%.

Gross Margin	65.95%
Operating Margin	14.38%
Pretax Margin	5.93%
Profit Margin	6.38%
EBITDA Margin	29.22%
EBIT Margin	14.38%
FCF Margin	14.91%

Dividends & Yields

This stock pays an annual dividend of 0.68, which amounts to a dividend yield of 2.60%.

Dividend Per Share	0.68
Dividend Yield	2.60%
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	101.62%
Buyback Yield	-1.07%
Shareholder Yield	1.53%
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Takeda Pharmaceutical Company has an Altman Z-Score of 1.17. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score	1.17
Piotroski F-Score	n/a